Last reviewed · How we verify
talazoparib plus enzalutamide (talazoparib-plus-enzalutamide)
Talazoparib and enzalutamide work synergistically to inhibit PARP and androgen receptor pathways, respectively, leading to enhanced DNA damage and reduced tumor growth in prostate cancer cells.
At a glance
| Generic name | talazoparib-plus-enzalutamide |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 3 |
| Annual revenue | 2194 |
Mechanism of action
Talazoparib blocks the PARP enzyme, preventing DNA repair, while enzalutamide inhibits the androgen receptor, reducing tumor growth signals. Together, they increase DNA damage and decrease survival of cancer cells.
Approved indications
Common side effects
- Anaemia
- Nausea
- Decreased appetite
- Asthenia
- Fatigue
- Constipation
- Platelet count decreased
- Oedema peripheral
- Diarrhoea
- Neutrophil count decreased
- Arthralgia
- Back pain
Key clinical trials
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (PHASE3)
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC (PHASE3)
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer (PHASE2)
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (PHASE2)
- Telmisartan in Prostate Cancer (PHASE1)
- Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (PHASE2)
- Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- talazoparib plus enzalutamide CI brief — competitive landscape report
- talazoparib plus enzalutamide updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI